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Sir,
We read with great interest the article by Kotsopoulos et al
(2007), which appeared recently in the British Journal of Cancer.
The authors addressed the question if carriers of BRCA1 mutations
can be detected by a reduced capacity to repair DNA double-strand
breaks (DSBs) before the onset of the disease. The answer would be
important because it could allow to develop such a technique into
a predictive test, which could be offered in high-risk families and
which might be applicable for a risk assessment for sporadic breast
cancer too.
DNA DSBs are repaired by either of the two repair pathways,
homologous repair (HR) or nonhomologous end joining (NHEJ).
Both processes, when successfully completed, do not leave open
ends and, hence, no DNA fragments are left. Mutations in BRCA1
(and BRCA2, which was not studied by Kotsopoulos et al, 2007)
have been shown to impair HR while NHEJ appears to be largely
unaffected (Venkitaraman, 2002). Nonhomologous end joining is
available throughout the cell cycle, while the activity of HR appears
in early S phase, when the template (the replicated DNA) becomes
available.
Kotsopoulos et al (2007) used three approaches to interrogate
DNA repair capacity and all three did not reveal a difference
between BRCA1 mutation carriers and controls. However, we have
some concerns about the conclusions and we would like to discuss
them in the order they take effect in the cell:
(1) The number of H2AX DNA repair granules was studied in
lymphocytes prepared directly from the blood sample, which
may indeed reflect DNA repair capacity under certain
circumstances and may be used to quantitate interindividual
variation (Ismail et al, 2007). However, the granules detected
by antibodies against H2AX are neither specific for DNA DSBs
(Bekker-Jensen et al, 2006; Au and Henderson, 2007) nor for
the HR repair pathway. The assembly of the granules does not
depend on the presence of BRCA1 (Foray et al, 2003). In
consequence, this test can be expected to be very sensitive
when early steps of damage recognition are involved but not
necessarily for haploinsufficiency of BRCA1. Furthermore, the
test has been carried out on lymphocytes in G0 in which the
amount of BRCA1 is rather low in any case (Venkitaraman,
2001). The use of anti-BRCA1 antibodies might have been
more informative, although one may expect to see differences
only in cells, which have entered the S phase.
(2) The alkaline Comet assay as used by the authors provides a
measure predominantly for the frequency of DNA single-
strand breaks but also detects DSBs and other DNA damage.
When used in the G0 phase of the cell cycle to determine DNA
repair capacity, the contribution of HR to this capacity is
certainly only a very minor point. Although there is evidence
that BRCA1 does not function exclusively in HR (Au and
Henderson, 2007), one cannot expect to detect small
differences in its activity (haploinsufficiency) by the comet
assay in G0 cells.
(3) The third assay used by Kotsopoulos et al (2007) was the
micronucleus test (MNT) with some variation compared to the
most frequently used protocols for the assessment of DNA
repair capacity. Among the assays used here, this is probably
the only assay, which in principle would be appropriate to
detect a difference in HR DNA repair as a consequence of a
heterozygous mutation in BRCA1. It has been used with rather
consistent results in breast cancer patients with and without
family history (Baeyens et al, 2004, 2005) and in some studies,
a reduced DNA repair capacity could be shown in BRCA1
mutation carriers (Rothfuss et al, 2000; Trenz et al, 2002).
The differences between the protocol used here and the usual
procedure relate to culture time (4 instead of 3 days) and to the
timing of the irradiation. Both may not be relevant because similar
variations in other assays (Scott et al, 1998, 1999; Baeyens et al,
2005) did not preclude the detection of a difference between cases
and controls. For the timing of irradiation, we can present some
systematic data obtained with high-dose rate (2Gy in 2min)
shifted through the culture time (Figure 1). Much more critical
seems the number of binucleated lymphocytes (BNCs), in which
the micronuclei were counted. This number was stated to be
minimally 200, which is definitely not sufficient to detect a
difference of 10% between the two groups, given the variability of
micronucleus counts (Vral et al, 2002; Patino-Garcia et al, 2006).
We investigated the influence of the number of BNCs counted on
the calculated mean MN frequency by incremental counting of
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exactly as described by Varga et al (2006). Counting was
performed by an automated system (Varga et al, 2004) to avoid
any variation possibly introduced by different observers and to
eliminate imperfect reproducibility (coefficient of variation of the
machine o5% for counts on the same slide). As obvious from
Figure 2, the deviation from the final mean decreases with an
increasing number of BNCs and becomes sufficiently small only
when more than 1000 BNCs are counted. In earlier studies, a lower
limit of 500 BNCs was used and some of the findings were
borderline (Baeyens et al, 2004; Speit and Trenz, 2004; Patino-
Garcia et al, 2006). In consequence, counting 200 BNCs, as by
Kotsopoulos et al, is not sufficient to state a negative result.
By now, ample evidence has accumulated to demonstrate that
lymphocytes from breast cancer patients have a slower or reduced
repair of DNA DSBs compared to healthy controls. This difference
can be detected by analysing chromosome aberrations or
micronuclei with various protocols. It can be also seen in breast
cancer patients with a BRCA1 mutation. The paper by Kotsopoulos
et al (2007) states correctly that BRCA1 mutation carriers cannot
be detected by the tests they employed using their protocols. They
addressed implicitly the important question whether a difference
in DNA repair capacity can rather be attributed to the disease
status (breast cancer) than to BRCA1 mutation. Investigating
BRCA1 mutation carriers without breast cancer should reveal
whether the reduced DNA repair capacity arises later on together
with the disease or can be detected before its onset and, hence, may
represent a direct consequence of the BRCA1 mutation. This
second view would be consistent with data from a prospective
study, in which increased baseline MN or chromosome aberration
frequencies indicated an increased cancer risk (Rossner et al, 2005;
Bonassi et al, 2007).
Two of the tests (H2AX foci and Comet assay) used by
Kotsopoulos et al (2007) were of questionable relevance concern-
ing the repair of DNA DSBs. The third one, the MNT, was not
carried out in a way, which could support a negative result. In
consequence, the important question implicated in the study
cannot be resolved: whether the reduced DNA repair capacity in
breast cancer patients with BRCA1 mutation is due to the cancer or
to the mutation. The answer to this question has to await more
specifically designed studies.
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Figure 1 Micronucleus frequencies plotted against time of irradiation.
Parallel lymphocyte cultures (72h) were irradiated with 2Gy (1Gymin
1)
at different time points after setting up the culture. Data points for each
proband are connected.
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Figure 2 Difference of MN frequency to the final mean MN frequency
of that culture plotted against the number of binucleated cells (BNCs) on
which the MN frequency was determined. It is obvious that the MN
frequencies close in on the final mean at numbers of 1000 or more
counted BNCs.
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